3.07
-0.1(-3.15%)
Currency In EUR
Address
Sant Ferran 74
Cornellà de Llobregat, 08940
Spain
Phone
34 93 515 13 13
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
47
First IPO Date
December 15, 2016
| Name | Title | Pay | Year Born |
| Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer & President | 477,000 | N/A |
| Mr. Jordi Xaus Pey | Scientific Director | 0 | N/A |
| Dr. Michael Thomas Ropacki Ph.D. | Medical Director of SNC | 0 | N/A |
| Ms. Neus Virgili Bernado | Director of Industrial Property | 0 | N/A |
| Mr. Emili Torrell Cortada | Director of Business Development | 0 | N/A |
| Mr. Augusto Pinel Rubio | Secretary | 0 | N/A |
| Ms. Sonia Paloma Gutierrez Bezon | Director of Clinical Operations | 0 | N/A |
| Mr. Enric Rello Condomines | Chief Operating Officer & Chief Financial Officer | 0 | N/A |
| Mr. Xavier Perpinya Ribera | Head of Internal Audit & Compliance | 0 | N/A |
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.